Top Sickle Cell Disease Treatment Companies

Sickle Cell Disease Treatment Market size was valued at USD 2.55 Billion in 2023 and is poised to grow from USD 3.1 Billion in 2024 to USD 14.6 Billion by 2032, growing at a CAGR of 21.4% during the forecast period (2025-2032).

Sickle cell disease treatment providers should focus on investing heavily in research and development to come up with novel treatments and therapies. Sickle cell disease treatment companies can also focus on gaining approvals for their novel treatment products and therapies from regulatory bodies and governments. Collaborations and partnerships are also expected to emerge as highly popular strategies for market players looking to enhance their revenue generation potential in the future.  'Novartis AG ', 'Emmaus Medical, Inc. ', 'Addmedica ', 'Medunik USA ', 'Global Blood Therapeutics, Inc. ', 'Bristol Myers Squibb Co. ', 'Sanofi SA ', 'Bluebird Bio ', 'Pfizer Inc. ', 'Aruvant Sciences, Inc. ', 'Glycomimetics, Inc. ', 'Editas Medicine, Inc. ', 'CRISPR Therapeutics ', 'F. Hoffmann-La Roche Ltd ', 'Janssen Pharmaceuticals ', 'Merck & Co., Inc. ', 'AstraZeneca ', 'Gilead Sciences ', 'Vertex Pharmaceuticals ', 'Hemanext'

Genetic predisposition and lack of early detection have resulted in a major hike in incidence of sickle cell disease around the world. Africa, India, and the Middle East are projected to key countries where the prevalence of sickle cell disease is high thereby making them highly opportune markets for sickle cell disease treatment providers as well. 

Collaborations to Increase Accessibility: Sickle cell disease treatment availability varies from region to region, and this has resulted in low adoption of novel treatments and therapies. Governments, non-profit organizations, and healthcare companies can team to improve accessibility and affordability of treatments for patients around the world to boost revenue generation in the long run.  

North America is estimated to lead the demand for sickle cell disease treatment on a global level. High investments in medical research, presence of a developed healthcare infrastructure, and high healthcare expenditure make this region a prime market for sickle cell disease treatment companies. Increasing willingness of patients in the United States to spend more on advanced treatment alternatives and growing medical tourism in the country allows it to emerge as the top market for sickle cell disease treatment companies operating in North America. Robust investments and advancements in gene therapies and technologies are also expected to help the dominance of this region in the long run.